Literature DB >> 23935106

Active glutaminase C self-assembles into a supratetrameric oligomer that can be disrupted by an allosteric inhibitor.

Amanda Petrina Scotá Ferreira1, Alexandre Cassago, Kaliandra de Almeida Gonçalves, Marília Meira Dias, Douglas Adamoski, Carolline Fernanda Rodrigues Ascenção, Rodrigo Vargas Honorato, Juliana Ferreira de Oliveira, Igor Monteze Ferreira, Camila Fornezari, Jefferson Bettini, Paulo Sérgio Lopes Oliveira, Adriana Franco Paes Leme, Rodrigo Villares Portugal, Andre Luis Berteli Ambrosio, Sandra Martha Gomes Dias.   

Abstract

The phosphate-dependent transition between enzymatically inert dimers into catalytically capable tetramers has long been the accepted mechanism for the glutaminase activation. Here, we demonstrate that activated glutaminase C (GAC) self-assembles into a helical, fiber-like double-stranded oligomer and propose a molecular model consisting of seven tetramer copies per turn per strand interacting via the N-terminal domains. The loop (321)LRFNKL(326) is projected as the major regulating element for self-assembly and enzyme activation. Furthermore, the previously identified in vivo lysine acetylation (Lys(311) in humans, Lys(316) in mouse) is here proposed as an important down-regulator of superoligomer assembly and protein activation. Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide, a known glutaminase inhibitor, completely disrupted the higher order oligomer, explaining its allosteric mechanism of inhibition via tetramer stabilization. A direct correlation between the tendency to self-assemble and the activity levels of the three mammalian glutaminase isozymes was established, with GAC being the most active enzyme while forming the longest structures. Lastly, the ectopic expression of a fiber-prone superactive GAC mutant in MDA-MB 231 cancer cells provided considerable proliferative advantages to transformed cells. These findings yield unique implications for the development of GAC-oriented therapeutics targeting tumor metabolism.

Entities:  

Keywords:  Cancer; Enzyme Inhibitors; Enzyme Mechanisms; Glutaminase; Metabolism; Warburg Effect

Mesh:

Substances:

Year:  2013        PMID: 23935106      PMCID: PMC3784714          DOI: 10.1074/jbc.M113.501346

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Regulation of renal ammoniagenesis. Purification and characterization of phosphate-dependent glutaminase from rat kidney.

Authors: 
Journal:  Arch Biochem Biophys       Date:  1976-05       Impact factor: 4.013

2.  Inorganic phosphate as regulator of adenosine formation in isolated guinea pig hearts.

Authors:  M W Gorman; M X He; C S Hall; H V Sparks
Journal:  Am J Physiol       Date:  1997-02

Review 3.  Targeting cancer metabolism--aiming at a tumour's sweet-spot.

Authors:  Neil P Jones; Almut Schulze
Journal:  Drug Discov Today       Date:  2011-12-22       Impact factor: 7.851

4.  Correlation between activation and dimer formation of rat renal phosphate-dependent glutaminase.

Authors:  S Godfrey; T Kuhlenschmidt; P Curthoys
Journal:  J Biol Chem       Date:  1977-03-25       Impact factor: 5.157

5.  Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism.

Authors:  Alexandre Cassago; Amanda P S Ferreira; Igor M Ferreira; Camila Fornezari; Emerson R M Gomes; Kai Su Greene; Humberto M Pereira; Richard C Garratt; Sandra M G Dias; Andre L B Ambrosio
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-06       Impact factor: 11.205

6.  The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type.

Authors:  Mariia O Yuneva; Teresa W M Fan; Thaddeus D Allen; Richard M Higashi; Dana V Ferraris; Takashi Tsukamoto; José M Matés; Francisco J Alonso; Chunmei Wang; Youngho Seo; Xin Chen; J Michael Bishop
Journal:  Cell Metab       Date:  2012-02-08       Impact factor: 27.287

7.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

Review 8.  Scaling and assessment of data quality.

Authors:  Philip Evans
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-12-14

9.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  34 in total

1.  Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.

Authors:  Qingqiu Huang; Clint Stalnecker; Chengliang Zhang; Lee A McDermott; Prema Iyer; Jason O'Neill; Shawn Reimer; Richard A Cerione; William P Katt
Journal:  J Biol Chem       Date:  2018-01-09       Impact factor: 5.157

2.  Conformational changes in the activation loop of mitochondrial glutaminase C: A direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activators.

Authors:  Clint A Stalnecker; Jon W Erickson; Richard A Cerione
Journal:  J Biol Chem       Date:  2017-02-14       Impact factor: 5.157

3.  The activation loop and substrate-binding cleft of glutaminase C are allosterically coupled.

Authors:  Yunxing Li; Sekar Ramachandran; Thuy-Tien T Nguyen; Clint A Stalnecker; Richard A Cerione; Jon W Erickson
Journal:  J Biol Chem       Date:  2019-12-23       Impact factor: 5.157

4.  Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells.

Authors:  Clint A Stalnecker; Scott M Ulrich; Yunxing Li; Sekar Ramachandran; Mary Kate McBrayer; Ralph J DeBerardinis; Richard A Cerione; Jon W Erickson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-29       Impact factor: 11.205

5.  Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.

Authors:  Nathalie Jacque; Anne Marie Ronchetti; Clément Larrue; Godelieve Meunier; Rudy Birsen; Lise Willems; Estelle Saland; Justine Decroocq; Thiago Trovati Maciel; Mireille Lambert; Laury Poulain; Marie Anne Hospital; Pierre Sujobert; Laure Joseph; Nicolas Chapuis; Catherine Lacombe; Ivan Cruz Moura; Susan Demo; Jean Emmanuel Sarry; Christian Recher; Patrick Mayeux; Jérôme Tamburini; Didier Bouscary
Journal:  Blood       Date:  2015-07-17       Impact factor: 22.113

6.  Targeting glutaminase-mediated glutamine dependence in papillary thyroid cancer.

Authors:  Yang Yu; Xiaohui Yu; Chenling Fan; Hong Wang; Renee Wang; Chen Feng; Haixia Guan
Journal:  J Mol Med (Berl)       Date:  2018-06-25       Impact factor: 4.599

Review 7.  From Krebs to clinic: glutamine metabolism to cancer therapy.

Authors:  Brian J Altman; Zachary E Stine; Chi V Dang
Journal:  Nat Rev Cancer       Date:  2016-07-29       Impact factor: 60.716

8.  SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis.

Authors:  Kai Su Greene; Michael J Lukey; Xueying Wang; Bryant Blank; Joseph E Druso; Miao-Chong J Lin; Clint A Stalnecker; Chengliang Zhang; Yashira Negrón Abril; Jon W Erickson; Kristin F Wilson; Hening Lin; Robert S Weiss; Richard A Cerione
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-16       Impact factor: 11.205

9.  The origin and evolution of human glutaminases and their atypical C-terminal ankyrin repeats.

Authors:  Camila Cristina Pasquali; Zeyaul Islam; Douglas Adamoski; Igor Monteze Ferreira; Ricardo Diogo Righeto; Jefferson Bettini; Rodrigo Villares Portugal; Wyatt Wai-Yin Yue; Ana Gonzalez; Sandra Martha Gomes Dias; Andre Luis Berteli Ambrosio
Journal:  J Biol Chem       Date:  2017-05-19       Impact factor: 5.157

10.  Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.

Authors:  Yan Xiang; Zachary E Stine; Jinsong Xia; Yunqi Lu; Roddy S O'Connor; Brian J Altman; Annie L Hsieh; Arvin M Gouw; Ajit G Thomas; Ping Gao; Linchong Sun; Libing Song; Benedict Yan; Barbara S Slusher; Jingli Zhuo; London L Ooi; Caroline G L Lee; Anthony Mancuso; Andrew S McCallion; Anne Le; Michael C Milone; Stephen Rayport; Dean W Felsher; Chi V Dang
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.